Results 11 to 20 of about 2,151,650 (259)

Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane [PDF]

open access: yes, 2002
p53 is a transcription factor that induces growth arrest or apoptosis in response to cellular stress. To identify new p53-inducible proapoptotic genes, we compared, by differential display, the expression of genes in spleen or thymus of normal and p53 ...
Bourdon, J.-C.; id_orcid   +9 more
core   +1 more source

Models incorporating chromatin modification data identify functionally important p53 binding sites [PDF]

open access: yes, 2013
Genome-wide prediction of transcription factor binding sites is notoriously difficult. We have developed and applied a logistic regression approach for prediction of binding sites for the p53 transcription factor that incorporates sequence information ...
Barker, Daniel   +2 more
core   +1 more source

Role of p53 serine 46 in p53 target gene regulation [PDF]

open access: yes, 2011
The tumor suppressor p53 plays a crucial role in cellular growth control inducing a plethora of different response pathways. The molecular mechanisms that discriminate between the distinct p53-responses have remained largely elusive.
Bianca Gilbert   +22 more
core   +2 more sources

The human adenovirus 5 L4 promoter is activated by cellular stress response protein p53 [PDF]

open access: yes, 2013
During adenovirus infection, the emphasis of gene expression switches from early genes to late genes in a highly regulated manner. Two gene products, L4-22K and L4-33K, contribute to this switch by activating the Major Late Transcription Unit (MLTU) and ...
Leppard, Keith, Wright, Jordan
core   +1 more source

Detección de aneuploidías del cromosoma 17 y deleción del gen TP53 en una amplia variedad de tumores sólidos mediante hibridación in situ fluorescente bicolor

open access: yesBiomédica: revista del Instituto Nacional de Salud, 2010
Introducción. El TP53 es un gen supresor de tumores localizado en la región cromosómica 17p13.1; controla el ciclo celular y se encuentra alterado en cerca de 50% de todas las neoplasias. Objetivos.
Juan Carlos Herrera   +4 more
doaj   +1 more source

Quantitative model for inferring dynamic regulation of the tumour suppressor gene p53 [PDF]

open access: yes, 2010
Background: The availability of various "omics" datasets creates a prospect of performing the study of genome-wide genetic regulatory networks. However, one of the major challenges of using mathematical models to infer genetic regulation from microarray ...
Junbai Wang   +5 more
core   +1 more source

A Comprehensive and High-Resolution Genome-wide Response of p53 to Stress

open access: yesCell Reports, 2014
Tumor suppressor p53 regulates transcription of stress-response genes. Many p53 targets remain undiscovered because of uncertainty as to where p53 binds in the genome and the fact that few genes reside near p53-bound recognition elements (REs).
Gue Su Chang   +11 more
doaj   +1 more source

Gene expression profiles resulting from stable loss of p53 mirrors its role in tissue differentiation. [PDF]

open access: yesPLoS ONE, 2013
The tumor suppressor gene p53 is involved in a variety of cellular activities such as cellular stress responses, cell cycle regulation and differentiation.
Oliver Couture   +4 more
doaj   +1 more source

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. [PDF]

open access: yes, 2011
BACKGROUND: The mammalian DNA-damage response (DDR) has evolved to protect genome stability and maximize cell survival following DNA-damage. One of the key regulators of the DDR is p53, itself tightly regulated by MDM2. Following double-strand DNA breaks
Valentine, Jane M.   +11 more
core   +2 more sources

Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways [PDF]

open access: yes, 2013
The DNA-damaging agent camptothecin (CPT) and its analogs demonstrate clinical utility for the treatment of advanced solid tumors, and CPT-based nanopharmaceuticals are currently in clinical trials for advanced kidney cancer; however, little is known ...
Ashcroft, M   +4 more
core   +2 more sources

Home - About - Disclaimer - Privacy